Raymond James initiated coverage on Avidity Biosciences with a new price target
$RNA
Biotechnology: Pharmaceutical Preparations
Health Care
Raymond James initiated coverage of Avidity Biosciences with a rating of Strong Buy and set a new price target of $65.00